Research Article
Diabetes Management and Outcomes among Patients with Type 2 Diabetes Attending a Renal Service
Table 3
Medications of patients according to insulin treatment status.
| | Medications | Number of patients (%) | | | Total | Insulin treated () | Noninsulin treated () |
| | Antihyperglycaemic agents | Metformin | 104 (38.8) | 37 (30.3) | 67 (45.9) | 0.009 | | Sulphonylurea | 81 (30.2) | 19 (15.6) | 62 (42.5) | <0.001 | | DPP4i | 66 (24.6) | 24 (19.7) | 42 (28.8) | 0.085 | | GLP-1 RA | 11 (4.1) | 5 (4.1) | 6 (4.1) | 0.996 | | SGLT2i | 15 (5.6) | 7 (5.7) | 8 (5.5) | 0.927 |
| | Antihypertensive | RAAS blocker¶ | 188 (70.1) | 89 (73.0) | 99 (67.8) | 0.360 | | ACEi | 61 (22.8) | 31 (25.4) | 30 (20.5) | 0.344 | | ARB | 131 (48.9) | 58 (47.5) | 73 (50.0) | 0.688 | | CCB | 133 (49.6) | 59 (48.4) | 74 (50.7) | 0.705 | | Beta blocker | 122 (45.5) | 59 (48.4) | 63 (43.2) | 0.394 |
| | Lipid lowering agents | Statin | 207 (77.2) | 105 (86.1) | 102 (69.9) | 0.002 | | Fibrate | 31 (11.6) | 19 (15.6) | 12 (8.2) | 0.061 | | Ezetimibe | 38 (14.2) | 18 (14.8) | 20 (13.7) | 0.805 |
| | Aspirin | Aspirin | 96 (35.8) | 50 (41.0) | 46 (31.5) | 0.107 |
| | Renal drugs | ESA | 56 (20.9) | 31 (25.4) | 25 (17.1) | 0.097 |
|
|
Pearson’s chi-square test, unless otherwise stated. ¶Includes individuals receiving an ACEi or ARB. DPP4i: dipeptidyl peptidase-4 inhibitor; GLP-1 RA: glucagon-like peptide 1 agonist; SGLT2i: sodium glucose co-transporter 2 inhibitor; RAAS blocker: renin-angiotensin-aldosterone system blocker; ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; ESA: erythropoietin stimulating agent.
|
